|
T.ONC
|
The end of phase I. are you kidding, this is a joke. Obviously we are not...
|
|
T.ONC
|
Posters seem to think this is positive news, I do not. To me it just means...
|
|
T.ONC
|
Seven weeks and counting, when Brad misses he misses big.
Unrelated here is...
|
|
T.ONC
|
The following abstract shows that KRAS mutation should not affect chemo...
|
|
T.ONC
|
Another study, the response rate varies some from study to study but survival...
|
|
T.ONC
|
Another good article on the two in combination
http://annonc.oxfordjournals...
|
|
T.ONC
|
Found this article and it seems that to the poster in some kind of context is...
|
|
T.ONC
|
I have been looking hard for response rates for this combination and found up...
|
|
T.ONC
|
The most difficult part will be understanding the poster when it comes out...
|
|
T.ONC
|
The interim report on the NSCLC trial is likely to be the most important news...
|
|
T.ONC
|
ASCO 201015-Apr-10 03:10 pm
#3080: A phase...
|
|
T.ONC
|
Six weeks only missed estimate by double and counting. I have to say that...
|
|
T.ONC
|
Hey! We have been discussing this since the second, we must have gotten...
|
|
T.ONC
|
I can remember when a mouse study like the latest one would have added...
|
|
T.ONC
|
Our results are clinically applicable in 2 distinct situations. First, in...
|
|
T.ONC
|
Good explanation of the mouse study. This may or may not be important to the...
|
|
T.ONC
|
http://www.jci.org/articles/view/41431This is a very interesting trial, it...
|
|
T.ONC
|
http://www.nytimes.com/2010/03/31/nyregion/31about.html
It will take years to...
|
|
T.ONC
|
It's not a big deal but Brad has missed his timeline again, he said...
|
|
T.ONC
|
I was aware of this company back when I used to own Oxygene a number of years...
|